Future Directions in Relapsed and Refractory Large B-cell Lymphoma

About this episode

This episode features a discussion on advancements in treating relapsed and refractory large B-cell lymphoma with Drs. Kamdar and Bartlett.

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “ From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma ”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

People in this episode

Host: Dr. Philippe Armand

Guests: Dr. Manali Kamdar, Dr. Nancy L. Bartlett

Topics covered

• relapsed large B-cell lymphoma
• chimeric antigen receptor T cells
• antibody-drug conjugates
• bispecific antibodies
• treatment paradigms

Keywords

• large B-cell lymphoma
• chimeric antigen receptor T cells
• antibody-drug conjugates
• bispecific antibodies
• chemotherapy

Mentioned in this episode

Organizations: Blood

Books & works: From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma

More episodes of Blood Podcast

• Review Series on Clonal Tracking in Hematopoiesis · June 4, 2026 · 30 min
• New Approaches: Marstacimab Therapy and HLH Biomarkers · May 28, 2026 · 18 min
• Review Series on Hemophagocytic Lymphohistiocytosis (HLH) · May 21, 2026 · 16 min
• IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria · May 14, 2026 · 21 min
• Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia · May 7, 2026 · 13 min
• Effects of ZNF467 on HSPC fitness and Promotion of Follicular Lymphoma via DC-SIGN · April 30, 2026 · 22 min